Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
NVAX(NASDAQ:NVAX) GAITHERSBURG, Md., Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine Nuvaxovid® Intramuscular Injection 1 mL formulated to target SARS-CoV-2 Omicron LP.8.1 as...
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
NVAXNuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™...
Novavax Announces Convertible Debt Refinancing
NVAXRefinancing extends maturity of most existing debt with improved terms $225 million of convertible notes due in 2031 issued, including a ~$175 million exchange for the retirement of existing convertible notes due in 2027 and ~$50 million of new money GAITHERSBURG, Md., Aug. 21, 2025...
Novavax Says Results Of Initial Cohort Of COVID-19-Influenza Combination And tNIV Phase 3 Trial Shows Both Vaccine Candidates Induced Immune Responses Similar To Licensed Comparators Nuvaxovid And Fluzone HD, Respectively
NVAXRFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks
NVAXThe U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced the Centers for Disease Control and Prevention will no longer recommend COVID-19 vaccines for healthy children and pregnant women, sparking criticism from public health experts who cite ongoing risks.
Novavax Eliminates Position Of COO And Terminates John Trizzino; Trizzino To Continue To Provide Consulting Services
NVAXWhat's Driving the Market Sentiment Around Novavax?
NVAXNovavax Reiterates Expectation To Achieve R&D Plus SG&A Expenses For FY25 Of Between $475M-$525M. For 2026 And 2027, Expects To Reduce R&D Plus SG&A Expenses To Approximately $350M And $250M, Respectively
NVAXJP Morgan Maintains Underweight on Novavax, Lowers Price Target to $7
NVAXCOVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
NVAXNovavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations.
Novavax Sees FY2025 Sales $975.000M-$1.025B vs $724.16M Est
NVAXNovavax Q1 EPS $2.93 Beats $0.71 Estimate, Sales $666.65M Beat $343.85M Estimate
NVAXUncovering Potential: Novavax's Earnings Preview
NVAXNovavax To Receive $19.5M Upfront Payment Under Amended Agreement With Takeda
NVAXFDA Asks Vaccine Maker To Complete New Clinical Trial For Delayed Covid-19 Shot; A New Randomized Study Could Cost Novavax Tens Of Millions Of Dollars, Vaccine Experts Say - WSJ
NVAXNovavax Believes Its Biologics License Application Is Approvable Based On Conversations With FDA As Of PDUFA Date On Apr. 1 And Through Today
NVAXNovavax Announces Prelim. Results From SHIELD-Utah Study Showing Co.'s Vaccine, Adjuvanted (2024-2025 Formula) Resulted In Fewer And Less Severe Reactogenicity Symptoms vs Pfizer-BioNTech mRNA 2024-2025 Vaccine
NVAX'Novavax Shares Plunge After RFK Jr. Questions Its Covid Vaccine' - Bloomberg News
NVAXDespite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
NVAXBiotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine (UPDATED)
NVAXNovavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.
Novavax Confirms That April 1, 2025, Was The U.S. FDA's Prescription Drug User Fee Act Date For It's Biologics License Application Seeking The Approval Its COVID-19 Vaccine
NVAX'FDA Misses Deadline For Covid-19 Vaccine Decision' - Wall Street Journal
NVAXNovavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
NVAXNovavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.
For 2025, Novavax Expects To Achieve Adjusted Licensing, Royalties And Other Revenue Of Between $300M-$350M, Ended Full Year 2024 With Over $1B In Cash And Accounts Receivables
NVAXNovavax Q4 2024 GAAP EPS $(0.51), Inline, Sales $88.31M Beat $84.38M Estimate
NVAXNovavax FY 2024 GAAP EPS $(1.23) Beats $(1.32) Estimate, Sales $682.16M Miss $684.94M Estimate
NVAXLooking Into Novavax's Recent Short Interest
NVAXWhy Novavax (NVAX) Stock Is Falling
NVAXNovavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates.
Why Novavax Stock Is Volatile This Week
NVAXNovavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC report on rising respiratory illnesses.
Peering Into Novavax's Recent Short Interest
NVAXWhy Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
NVAXNovavax ends UK COVID-19 vaccine contract, agreeing to repay $123.8M in quarterly installments by 2027 as part of settlement.
How Is The Market Feeling About Novavax?
NVAXNovavax And UK Health Security Agency End Disputes Over Vaccine Supply; Novavax To Refund $123.8M In Quarterly Installments Until 2027; First Payment Due November 30, 2024
NVAXCDC Reports Second Human Case Of H5 Bird Flu Linked To Dairy Cow Outbreak In Michigan; Says Risk Assessment For General Public Remains Low
NVAXNovavax Says Distribution Of R21/Matrix-MTM Across The African Region Is Expected To Begin In Coming Weeks
NVAXShah Capital Withdraws Proxy Campaign Against Re-election Of Directors At Novavax's 2024 Annual Meeting, Shah Capital Management Collectively Beneficially Owns ~7.9% Of Novavax's Shares, Making It A Top Three And Largest Non-index Stockholder
NVAXNovavax Exec At Baird's Global Healthcare Conference Says Expect To Continue To Ship Prototype Vaccine Beginning In Next Year Before Getting Into Annual Vaccination Cycle
NVAXNovavax Exec At Baird's Global Healthcare Conference Says Still Shipping Prototype Vaccine Into Countries, Expect To Continue To Do That Through Year-end
NVAXNovavax And Serum Institute Of India Announce Full Product Registration In South Africa Of Novavax COVID-19 Vaccine As A Primary Series For Adults Aged 18 And Older
NVAXNovavax Reissuing Letter Of Authorization To FDA On August 19, To Authorize Use Of Novavax Covid-19 Vaccine, Adjuvanted For People 12 Through 17 Years Of Age; Reissuing Letter To Revise Conditions Of Authorization Related To VAERS Reporting Requirements F
NVAXEurope Approves Novavax's COVID-19 Vaccine Booster For Adults
NVAXNovavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization In The European Union For Use As A Booster For Adults Aged 18 And Older
NVAXNovavax Reports Requested Expanded Authorization For ITs COVID-19 Vaccine To Adolescents Aged 12-17 Years In UK
NVAXNovavax Whale Trades For May 03
NVAXA whale with a lot of money to spend has taken a noticeably bearish stance on Novavax.
Looking at options history for Novavax (NASDAQ:NVAX) we detected 45 strange trades.
Novavax Reports FDA's Vaccines, Related Biological Products Advisory Committee Will Review Co.'s COVID-19 Vaccine At A Meeting Scheduled For Jun. 7, 2022
NVAXHere's How Much $100 Invested In Novavax 5 Years Ago Would Be Worth Today
NVAXNovavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 13.46% on an annualized basis producing an average annual return of 25.46%. Currently, Novavax has a market capitalization of $3.83 billion.
This Is What Whales Are Betting On Novavax
NVAXA whale with a lot of money to spend has taken a noticeably bullish stance on Novavax.
Looking at options history for Novavax (NASDAQ:NVAX) we detected 17 strange trades.
